Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...
There is a simple discount patient access scheme for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Healthy eating and weight management in pregnancy, and healthy eating in children up to 5 years: the care you should expect Eating well before, during and after pregnancy means that both mother and ...
Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the perioperative ...
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. Not eligible? Contact the stakeholder organisation that most closely represents your interests and ...
Evidence on interventions to improve the uptake of folic acid supplementation before and during pregnancy showed mixed findings. Overall, information provision and education interventions compared ...
Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...
Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the ‘Inputs and eligible population’ and ‘Unit costs’ worksheets in the template to reflect ...